• CV Sciences’ third-quarter 2026 net loss narrowed 76% year over year to $93,000.
• Operating results swung to income of $377,000 from a year-earlier loss, mainly due to a $500,000 legal settlement gain and expense reductions.
• Revenue fell 7% year over year to $3.03 million, driven by lower sales volume due to restrictive federal and state regulations.
• The company expanded its +PlusHLTH portfolio with personalized wellness solutions for healthy aging.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CV Sciences Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202611121600ACCESSWRNAPR_____1250405) on November 12, 2026, and is solely responsible for the information contained therein.